Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism

Neurology

Volumn 57, Issue 3, 2001, Pages 410-416

  Graf, William D ^a,c   Unis, A S ^b   Yates, C M ^b   Sulzbacher, S ^b   Dinulos, M B ^a   Jack, R M ^a   Dugaw, K A ^a   Paddock, M N ^a   Parson, W W ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c The ACCORD Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ADRENALIN; BENZATROPINE; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; DNA; DOPAMINE; HOMOVANILLIC ACID; METIROSINE; NORADRENALIN; S ADENOSYLMETHIONINE; VANILMANDELIC ACID;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CHROMOSOME 22Q; CHROMOSOME DELETION; CLINICAL TRIAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREMOR;

EID: 0035859844     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.3.410     Document Type: Article

References (38)

1. Velo-cardio-facial syndrome: A distinctive behavioral phenotype
2. Chromosome 22q11 deletions. An under-recognized cause of idiopathic learning disability
3. DiGeorge and velocardiofacial syndromes: The 22q11 deletion syndrome
4. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: A European collaborative study
5. Velo-cardiofacial-syndrome. A review of 120 patients
6. Velo-cardiofacial syndrome. Language and psychological profiles
7. Intelligence and psychosocial adjustment in velocardiofacial syndrome: A study of 37 children and adolescents with VCFS
8. Deletion 22q11. A newly recognized cause of behavioral and psychiatric disorders
9. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives
10. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11
11. Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: Does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder?
12. Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome
13. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.11-11.2
14. Localization of 4 catechol-O-methyltransferase in the leptomeninges, choroid plexus and ciliary epithelium: Implications for the separation of central and peripheral catechols
15. Inheritance of low erythrocyte catechol-O-methyltransferase activity in man
16. Possible role for COMT in psychosis associated with velo-cardio-facial syndrome
17. Schizophrenia: More dopamine, more D2 receptors
18. Kinetics of human soluble and membrane bound catechol-O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme
19. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome
20. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder
21. Ultraultra rapid cycling bipolar disorder is associated with the low activity catecholamine-O-methyltransferase allele
22. Effects of methyltyrosine on the cerebral fluid content of HVA and 5HIAA in man
23. Effects of reserpine and a tyrosine hydroxylase inhibitor on the monoamine levels in different regions of the rat central nervous system
24. Florescent histochemical studies on the uptake, storage and release of catecholamine
25. Consed: A graphical tool for sequence finishing
26. Does carnitine administration improve the symptoms attributed to anticonvulsant medications? A double-blinded, crossover study
27. Plasma 3,4-dihydroxyphenylalanine (DOPA) is independent of sympathetic activity in humans
28. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease
29. High-performance liquid chromatographic assay of free norepinephrine, epinephrine, dopamine, vanillylmandelic acid and homovanillic acid
30. Simultaneous liquid-chromatographic analysis for 4-hydroxy, 3-methoxymandelic acid and 4-hydroxyl, 3-methoxyphyenylacetic acid in urine
31. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: Effects of treatment with parenteral and oral S-adenosylmethionine
32. Homocysteine, folate, methylation, and monoamine metabolism in depression
33. A radioenzymatic method for S-adenosylmethionine determination in biological fluids
34. Neuropharmacology of S-adenosylmethionine
35. Pharmacological rescue of mutant p53 conformation and function
36. Age effect on dopamine and serotonin metabolite levels in cerebrospinal fluid
37. Crystal structure of catechol-O-methyltransferase
38. The MIDAS display system